Study of Mevrometostat for Advanced Prostate Cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of prostate cancer called adenocarcinoma (not small cell).
- Your cancer has spread to your bones or soft tissue (like lymph nodes).
- Your cancer is still growing despite hormone therapy for castration.
- You are in good physical condition (ECOG score 0 or 1) and expected to live at least 12 more months.
- You have not had any treatment for this stage of cancer (metastatic castration-resistant) except for certain earlier therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This study tests two new drugs, regn21353 and nezastomig, alone or together, in men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if these drugs can help slow the cancer's growth.
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.